Raymond James analyst John Ransom downgraded Oak Street Health (OSH) to Market Perform from Outperform without a price target following CVS Health’s (CVS) announcement that it will buy the company for $10.6B. The firm is stepping to the sidelines as the stock has run up to the $35 price target as the remaining ~$4 will be a grind until the deal is ultimately closed, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OSH:
- Oak Street Health downgraded to Market Perform from Outperform at Raymond James
- CVS Health price target raised to $143 from $130 at Jefferies
- Oak Street Health downgraded to Hold from Buy at Jefferies
- Oak Street Health downgraded to Market Perform from Outperform at William Blair
- Oak Street Health downgraded to Hold from Buy at Canaccord